Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases.
Oruka Therapeutics has raised $700.4M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in April 2026.
Oruka Therapeutics's investors include Cormorant Asset Management, Perceptive Advisors, Redmile Group, Great Point Partners, RTW Investments.
Oruka Therapeutics is headquartered in Waltham, United States.
Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases.
Oruka Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Oruka Therapeutics — Funding & Investors." VCBacked, April 28, 2026, https://www.vcbacked.co/company/oruka-therapeutics. Accessed July 19, 2026.
VCBacked. (2026). Oruka Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/oruka-therapeutics
{{cite web |title=Oruka Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/oruka-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated